HERE is evidence from various clinical and in vitro studies that indicate that induction of hypothermia in patients with severe head injury may prevent additional brain injury and improve neurological outcome. 2, 7, 16, 30, 35, 37 Apart from the decreases in oxygen and glucose metabolism that are induced by cooling, it seems likely that other mechanisms are involved, because the protective effects of hypothermia appear to be greater than that which can be explained by the effects on metabolism alone. 5, 8, 19 Various deleterious chemical cascades and pathophysiological changes such as cerebral thermopooling taking place in the brain following neurological trauma appear to be suppressed even by mild hypothermia.
by cranial trauma. 12 In addition, these patients are often treated with mannitol, which also induces polyuria. In this way, various mechanisms combine to place patients with severe head injury at risk for development of polyuria.
Excessive diuresis can lead to the loss of various electrolytes including Mg, K, and phosphate. This can have serious clinical implications and consequences. Magnesium ions are important for regulation of the transportation of Na and K across membranes through activation of a Na-K adenosine triphosphatase pump. Low Mg levels can cause cardiac arrhythmias, neuromuscular irritability, hypertension, and vasoconstriction. 20 Hypomagnesemia is associated with an increased risk of mortality in the ICU. 6, 27 Hypokalemia can also induce cardiac arrhythmias, especially in patients with ischemic heart disease and left ventricular hypertrophy, and is associated with muscle weakness, rhabdomyolysis, renal failure, and hyperglycemia. Phosphate is important for maintaining muscle tone; hypophosphatemia is associated with low intracellular levels of adenosine triphosphate, 22 and low phosphate levels can lead to muscle weakness, respiratory failure, and a decrease in cardiac output. 9, 10 Hypophosphatemia also impairs the contractile properties of the diaphragm in critically ill patients, leading to difficulties in weaning them from reliance on the respirator. 1 Low phosphate levels may also be associated with decreased cardiac output and with ventricular tachycardia after myocardial infarction, 22 and may be a superimposed cause of myocardial depression, inadequate peripheral vasodilation, and acidosis associated with septic shock. 3 Moreover, when more than one of these electrolyte deficiencies is present, the effects may be cumulative, especially in Mg and K deficiency.
Thus, loss of Mg, K, and phosphate can lead to severe adverse effects, especially arrhythmias, in patients in the ICU. Moreover, because both low body temperature 33 and neurological trauma 38 are independently associated with severe arrhythmias, the clinical effects of electrolyte disorders might be enhanced in this category of patients. We therefore decided to study the effects of therapeutic hypothermia on urine production and electrolyte levels in patients with severe head injury.
Clinical Material and Methods

Study Protocol
In our hospital, patients with severe head injury are treated according to a step-up protocol (Fig. 1) . The primary goals of therapy include the following: stabilization or improvement of the patient's neurological condition, maintenance of ICP at 20 mm Hg or lower (normal value in healthy individuals Յ 15 mm Hg), and maintenance of CPP (that is, mean arterial pressure minus ICP) at 70 mm Hg or higher. In patients with a GCS 34 score of 8 or lower, the protocol includes insertion of a cranial probe (Camino probe; Integra LifeSciences, Plainsboro, NJ) for measuring ICP, appropriate sedation, treatment with muscle paralyzers, and administration of mannitol (maximum dose: 100 ml of a 20% solution given intravenously eight times daily). If the patient's ICP rises above 20 mm Hg, treatment with barbiturates (pentobarbital bolus 100-200 mg, followed by a continuous infusion of 100-300 mg/hour) is initiated. The effects are monitored using electroencephalography to measure burst suppression. If the patient's ICP remains higher than 20 mm Hg or rises above this cut-off level, despite the aforementioned therapy, therapeutic hypothermia is initiated with the aim of lowering body temperature to 32˚C, to reduce ICP, and to improve neurological outcome.
Hypothermia is induced by cooling the patient's body surface with water-circulating blankets (blanket temperature: 1-4˚C). The core body temperature is monitored continuously through measurements obtained via a rectal probe. Once the targeted core temperature has been achieved, this temperature is maintained by keeping the thermostat of the water-circulating blankets set at or slightly below 32˚C.
Patient Population
All patients with severe head injury who were treated using either a combination of hypothermia and pentobarbital or pentobarbital alone, during the period between January 1, 1997, and July 1, 1999, were included in our study. If a patient had sustained a severe head injury and required treatment with pentobarbital, he or she was included in our protocol. If ICP decreased sufficiently in response to pentobarbital therapy, the patient was included in the control group (Group 2). If ICP did not decrease sufficiently, therapeutic hypothermia was initiated and the patient was included in the study group (Group 1). Thus, our control group was comparable to our study group in all aspects (including treatment with pentobarbital, mannitol, and vasoactive medication), except for the addition of therapeutic hypothermia. In addition, because serum electrolyte levels were measured sequentially, individual patients could serve as their own controls; any effects that occurred only during the cooling period were deemed likely to have been an effect of the hypothermia.
Forty-two patients with severe head injury who were admitted to our ICU during the study period met our inclusion criteria; all of these patients were enrolled in the study. Twenty-two patients (Group 1) underwent therapeutic hypothermia; 20 patients responded sufficiently to pentobarbital administration and were used as controls (Group 2). In one patient in Group 1 severe arrhythmias developed, necessitating discontinuation of the cooling period after less than 4 hours. This patient was excluded from further analysis.
Patient characteristics such as age, volume of fluids infused, and dopamine and mannitol administration were similar in the two groups ( Table 1 ). The GCS scores at admission were slightly higher and the ICPs and APACHE II scores 14 were slightly lower in the control patients (Group 2), reflecting the less severe head injury in this group (although these differences were not statistically significant). Seven patients had a GCS above 8 at admission; these patients' conditions subsequently deteriorated, necessitating insertion of an intracranial probe to assist in ICP measurement, according to our protocol. None of the patients had a medical history of renal disease, diabetes mellitus, short bowel syndrome, or other diseases associated with electrolyte disorders.
The study was approved by the hospital ethics committee. In Group 1, plasma levels of Mg, phosphate, K, Na, and Ca were measured three times during the 6-hour period preceding induced hypothermia, and three times during the 6-hour period after the start of cooling. In Group 1, samples were taken after at least 4 hours of cooling. If patients received supplementation of the electrolytes during the 6-hour period before cooling and/or during cooling, the amounts administered were noted. In Group 2, three measurements were obtained when pentobarbital administration was initiated and an additional three measurements during the 6-hour period after ICP had decreased below 20 mm Hg. Samples were obtained between 4 hours and 6 hours after normalization of ICP.
Before pentobarbital administration and/or hypothermia induction, conventional ICP reduction therapy (as described earlier and shown in Fig. 1 ) was given to all patients; this remained unchanged throughout the study. All hypothermia-treated patients and control patients were given vasoactive mediators (dopamine and norepinephrine) to maintain CPP at no less than 70 mm Hg; the average quantities administered remained unchanged throughout the time period during which therapeutic hypothermia was in effect.
Statistical Analysis
Analysis of variance for repeated measurements was used for a comparison of electrolyte levels before, during, and after induced hypothermia. The Student t-test for paired results and, whenever necessary, the Fisher exact test were used for a comparison of pooled measurements of electrolyte levels. Group values are expressed as the means Ϯ SD.
Results
Induction of Hypothermia
The average time from admission to the ICU to induction of hypothermia was 28 hours. A rectal probe was used for continuous measurements of core temperature in all patients. Temperature was maintained at 34˚C instead of 32˚C in two patients, because of side effects of cooling. In all other patients temperatures below 33˚C were achieved at 3 hours and below 32.5˚C at 4 hours after initiation of therapeutic hypothermia. The average temperature 4.3 hours after the initiation of cooling was 31.8 Ϯ 0.8˚C.
Effect of Cooling on ICP and Various Clinical Parameters
The mean ICP before the start of therapeutic hypothermia was 36 Ϯ 19 mm Hg (range 24-68 mm Hg). Intracranial hypertension decreased markedly in all patients during the cooling period, to 15 Ϯ 8 mm Hg (range 5-31 mm Hg). Intracranial pressures of 20 mm Hg or less were achieved within 2 hours in 11 patients, within 4 hours in 16 patients, and within 8 hours in 19 patients. In one patient ICP decreased from 63 to 31 mm Hg, but remained higher than the targeted value of 20 mm Hg. Treatment was discontinued in one patient and modified in two patients because of side effects (see later discussion). There were no significant rebound effects after rewarming. Arrhythmias occurred in all patients, but in most cases these were not serious. Therapeutic hypothermia was discontinued because of ventricular arrhythmias in one patient and, in two patients, core temperature was maintained at 34˚C instead of 32˚C to prevent development of more serious arrhythmias. Seven patients were treated with antiarrhythmic agents during the study period, including sotalol HCl (20 mg, two patients), flecainide acetate (one patient), lidocaine HCl (one patient), and amidarone HCl (six patients); three patients were treated with more than one of these agents. Two other patients were treated with isoprenaline because of severe sinus bradycardia. All patients received dopamine (average 20.8 mg/hour) and norepinephrine (average 0.62 mg/hour) to maintain CPP. Patients remained hemodynamically stable throughout the cooling period. In six patients, measurements of cardiac output obtained using a pulmonary artery catheter established a 23% decrease compared with baseline when core temperatures below 33˚C were achieved, as expected in view of the decrease in metabolism induced by cooling.
In the ICU, the mortality rate in patients treated using hypothermia was 71%; the total in-hospital mortality rate was 76%. Of the five surviving patients, excellent neurological outcomes were achieved in three, with no (two patients) or slight (one patient) neurological disabilities observed at 6 months after discharge. The average predicted ICU mortality rate according to the APACHE II scores of these patients was 94%. In the control group, the mortality rate was 70% in the ICU and 75% throughout hospitalization. The predicted mortality rate in these patients in the ICU, according to their APACHE II scores, was 80%.
Electrolyte Levels
Electrolytes were measured three times before and three times during cooling (Tables 2-5 ). The second sets of ‡ Average amount each patient received during a 6-hour period before and a 6-hour period after cooling (50-100 ml six-eight times daily).
§ At 4.3 hours after cooling began. A GCS score of 15 on hospital discharge.
measurements were taken after 4, 5, and 6 hours of cooling-that is, after body temperatures below 32.5˚C had been achieved in all patients (except the two patients in whom temperature was maintained at 34˚C). Mean values of the three measurements are shown. In the control patients (Group 2), measurements were obtained during pentobarbital administration, three measurements before and three after normalization of ICP ( Tables 2 and 3 . However, in most of these patients hypomagnesemia and hypophosphatemia developed, despite supplementation. Potassium levels were determined on a routine basis every 2 hours, and relatively large amounts of supplementation were given to most patients (average 6 mmol/hour before cooling and 12 mmol/hour during cooling). Despite this, serum levels of K decreased in 15 of 21 patients, and mean serum levels decreased from 4.2 Ϯ 0.59 to 3.6 Ϯ 0.7 mmol/L during the cooling period (p Ͻ 0.01; Table 3 ).
In control patients (Group 2), no such variations in electrolyte levels were observed ( Table 4 ). The amounts of electrolyte supplementation required to maintain electrolyte homeostasis were comparable to the amounts administered to our patients before initiation of therapeutic hypothermia.
Urine Production and Electrolyte Excretion
The mean urine production before cooling was 219 Ϯ 70 ml/hour (Table 5 ). This relatively high urine production was probably due to the high infusion volume (our protocol includes induction of a hypertensive/hyperdynamic state; Fig. 1 ) and to treatment with mannitol. Urine production increased significantly during induced hypothermia, from 219 Ϯ 70 ml/hour (range 130-430 ml/hour) to 485 Ϯ 209 ml/hour (range 267-1120 ml/hour).
Concentrations of phosphate, K, and Mg in urine were measured before and during the cooling period in 10 of our Group 1 patients. The results are shown in Table 5 . Total excretion of all electrolytes increased significantly during the cooling period (p Ͻ 0.01).
Once the targeted core temperature of 32˚C was achieved in our patients and temperatures were stabilized at this level, urine production decreased to levels compa- rable to those measured before the cooling period (241 Ϯ 102 ml/hour). Electrolyte levels then started to rise in response to high-dose supplementation, after which the amounts infused could be swiftly reduced. In control patients (Group 2), average urine production and electrolyte excretion were comparable to levels measured before the cooling period in our study group (Group 1; Table 5 ).
Discussion
Our results show that induction of hypothermia in patients with cranial trauma can lead to severe depletions of Mg, phosphate, K, and, to a lesser degree, Ca. This may be the mechanism underlying the most important and serious side effect in patients treated with hypothermia: namely the induction of cardiac arrhythmias. This probably applies not only to patients with severe head injury but also to those who undergo therapeutic hypothermia for other reasons, including patients with stroke or postanoxic coma following CPR. We found that at least one mechanism by which this occurs is an increase in the urinary loss of electrolytes. However, other mechanisms, such as increased intracellular shift, may be involved because the amounts of electrolytes excreted in urine cannot in themselves be used to explain all the changes in serum electrolyte levels in our patients. This view is confirmed by the fact that hypokalemia and/or hypomagnesemia developed in many of our patients, despite the fact that they received substantial amounts of intravenous electrolyte supplementation. In some of our patients, the quantity of electrolytes given intravenously exceeded the amounts excreted in their urine; however, despite this apparently adequate supplementation, there were low serum levels of these electrolytes in these patients.
Electrolyte fluxes can be influenced by pH and, because hypothermia can induce acidosis, this could cause an intracellular shift of positively charged electrolytes, especially K. Indeed, the average pH decreased from 7.37 to 7.31 in our patients during the cooling period. However, although factors such as intracellular shift may thus have contributed to the development of electrolyte depletion, it seems clear that increased urine production played an important role. This view is corroborated by the substantial increase in electrolyte excretion observed in our study during the cooling period. In our patients, various risk fac- tors combine to increase the risk of polyuria and electrolyte loss. The first is a huge increase in urine production induced by hypothermia (hypothermia-induced diuresis). Second, neurological trauma itself is associated with polyuria, through induction of diabetes insipidus and other, as yet unknown mechanisms. 12 Third, all our patients were treated with a high-volume infusion to help induce a hypertensive and hyperdynamic state. Indeed, although urine production increased substantially during the cooling period, urine volumes were already quite high before cooling was initiated.
Despite the large volume of urine production resulting from induced hypothermia in our patients, if renal function were normal, the kidney should have reabsorbed most of the excreted electrolytes. This indicates a degree of renal dysfunction in our patients, despite normal serum creatinine levels. Reabsorption of Mg takes place mainly in the ascending loop of Henle and, to a lesser degree, in the distal tubule, which is the main site of Mg regulation. 39 Reabsorption of phosphate occurs mainly through passive reabsorption in the proximal tubule and, to a lesser extent, through active reabsorption in the distal tubule (largely dependent on parathyroid hormones). 26, 39 Potassium is reabsorbed mainly in the proximal tubule (passively) and the ascending loop of Henle (actively). Active secretion occurs in the distal and collecting tubule; normally this is reduced when serum levels of K are low. As outlined earlier, our findings indicate that tubular dysfunction was presumably present in our patients before therapeutic hypothermia was initiated; as a result of this tubular dysfunction, our patients were unable to compensate for the large increase in urine volume induced by hypothermia by increasing tubular reabsorption of electrolytes. This led to a substantial increase in electrolyte loss, which contributed to the development of serum electrolyte depletion.
The cause of tubular dysfunction in our patients is unknown. Some medications used in their treatment may have played a role. All our patients were treated with dopamine, which can enhance renal excretion of sodium and other electrolytes, 31 and with catecholamines, which can contribute significantly to the development of hypophosphatemia. 4 All patients were treated with mannitol, which increases urine production (osmotic diuresis). Four of our patients were also treated with aminoglycosides. Other factors that may have contributed to electrolyte deficiencies in our patients include nasogastric suction (two patients), diarrhea (one patient), and alcoholism (one patient). However, electrolyte deficiencies occurred in all patients who underwent therapeutic hypothermia, whereas the aforementioned factors (except treatment with dopamine and mannitol) were present in only a minority of patients. Moreover, these factors were already present before induction of hypothermia, whereas low electrolyte levels arose in most patients only after cooling was initiated. Last, the amounts of dopamine and mannitol given to our study patients (Group 1) were comparable to the amounts given to control patients (Group 2) in whom neither electrolyte depletion nor increased urine production developed. Thus, increased urinary excretion resulting from induced hypothermia (as demonstrated in our study) and increased intracellular shift appear to be the most likely causes of electrolyte depletion in our patients.
We previously reported that hypomagnesemia, hypophosphatemia, and hypokalemia are frequently present in patients with severe head injury at the time of admission. 23 In addition, such patients are often treated with high volumes of intravenous Mg-, phosphate-, Ca-, and K-free fluids to induce a hyperdynamic state. Mannitol, which can induce osmotic diuresis and electrolyte loss, is frequently used in such patients to decrease ICP. In this way, various factors may combine to place patients with head injury at risk for the development of severe electrolyte depletion.
The results of our current study show that induction of hypothermia dramatically increases this risk. This may be one of the mechanisms underlying the severe arrhythmias associated with low body temperatures and therapeutic hypothermia. In our protocol for treatment of patients with severe head injury, hypothermia was used as an option of last resort for patients who failed to respond to other treatment modes. Expected outcomes in these patients, thus, were extremely unfavorable. Viewed from this perspective, the effects of therapeutic hypothermia appear promising, with decreases in ICP in all patients during cooling and favorable neurological outcomes achieved in three patients. However, the number of patients in this series was too small for us to assess the overall effect of cooling on outcome, and patient selection may have played a role.
Therapeutic hypothermia is used clinically to prevent or limit postischemic neuronal damage, to control critically elevated ICP values in patients with severe head injury 2, 7, 16, 18, 21, 30, 35, 38 or stroke, 28, 29 and to improve outcomes in patients suffering from postanoxic coma after receiving CPR. 22, 32 Side effects of moderate hypothermia appear to be limited, although prolonged moderate hypothermia carries risks of arrhythmias, infection, and coagulopathies. 15 Although the possibility of a hypothermia-induced coagulopathy has not yet been excluded, the short-term use of hypothermia does not appear to increase the risk for intracranial hemorrhagic complications in patients with head injury. 25 Thus, the development of arrhythmias appears to be the most frequently occurring and most serious side ef- fect of therapeutic hypothermia. Indeed, the occurrence of arrhythmias has plagued ongoing clinical trials of hypothermia in patients with severe head injury. 24 Hypomagnesemia, hypokalemia, hypocalcemia, and, to a lesser degree, hypophosphatemia are all associated with various forms of cardiac arrhythmia, especially if more than one of these electrolytes is depleted. Cerebral injury in itself is associated with myocardial damage and various electrocorticographic abnormalities. 13 Development of electrolyte disorders reported in the present study may substantially increase the risk and severity of these complications after brain injury. This would also apply to other patients who undergo therapeutic hypothermia, particularly patients suffering from postanoxic coma following CPR and/ or myocardial infarction.
Depletion of Mg, phosphate, and K is associated with adverse outcomes and increased risk of mortality in patients admitted to the ICU. 1, 3, 6, 9, 10, 20, 27 The authors of animal studies have shown that Mg depletion is associated with increased tissue injury after experimental brain trauma, and that both preinjury and postinjury administration of Mg can improve outcome and decrease brain injury. 17, 36 Doctors in the ICU should be aware of this potential (and preventable) problem. Physicians should also be aware that electrolyte loss resulting from induced hypothermia can be profuse and that a substantial amount-much larger than would normally be expected-of electrolyte supplementation may be required to prevent clinical deficiencies. This point is illustrated by the fact that in some of our patients severe electrolyte depletion developed, in spite of substantial amounts of intravenously administered supplements. Therefore, electrolytes, including Mg and phosphate, should be measured frequently in patients with cranial trauma, especially when cooling is initiated as a treatment for high ICP. In our hospital we have now included initial supplementation and frequent monitoring of Mg, phosphate, K, and Ca (especially when and if cooling is initiated) in our protocol for the treatment of patients with severe head injury. All patients requiring therapeutic hypothermia now receive a bolus dose of Mg and a continuous infusion of phosphate before cooling is initiated; K supplementation, which most of these patients already receive, is usually increased when cooling is started, and electrolyte levels are measured frequently at the patient's bedside.
In our study, we found that polyuria, electrolyte loss, and the amounts of supplementation required decreased when targeted core temperatures were reached. Therefore, supplementation should be reduced at this point to prevent overshooting the goal, such as induction of hyperkalemia, and so forth.
In conclusion, our study clearly demonstrates that induction of hypothermia in patients with severe head injury is associated with severe electrolyte depletion, which is at least partly due to increased urinary excretion through hypothermia-induced polyuria. Patients with severe head injury are already at risk for electrolyte loss through various other mechanisms. Doctors treating these patients and other patients who undergo therapeutic hypothermia should be aware of this phenomenon. Prophylactic supplementation of Mg, K, phosphate, and Ca should be considered, and electrolytes should be monitored regularly in all patients who undergo therapeutic hypothermia.
